View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Chapter 2.5<br />
118<br />
13. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin<br />
P, Goodman Z, Delaney WEt, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F.<br />
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during<br />
adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8.<br />
14. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher<br />
P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. Peginterferon<br />
alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with<br />
chronic hepatitis B. Hepatology 2006;44:675-84.<br />
15. Gish RG, Lau DT, Schmid P, Perrillo R. A Pilot Study of Extended Duration Peginterferon<br />
Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B. Am J Gastroenterol<br />
2007;102:2718-23.<br />
16. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatmentrelated<br />
HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg<br />
levels. Antivir Ther 2007;12:73-82.<br />
17. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne<br />
A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P.<br />
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated<br />
interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7.<br />
18. Deguchi M, Yamashita N, Kagita M, Asari S, Iwatani Y, Tsuchida T, Iinuma K, Mushahwar IK.<br />
Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle<br />
immunoassay. J Virol Methods 2004;115:217-22.<br />
19. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G,<br />
MacSween RN, et al. Histological grading and staging of chronic hepatitis. J Hepatol<br />
1995;22:696-9.<br />
20. European Association For The Study Of The L. EASL Clinical Practice Guidelines: Management<br />
of chronic hepatitis B. J Hepatol 2009;50:227-42.<br />
21. Mazumdar M, Smith A, Bacik J. Methods for categorizing a prognostic variable in a multivariable<br />
setting. Stat Med 2003;22:559-71.<br />
22. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-<br />
Pacifi c consensus statement on the management of chronic hepatitis B: a 2008 update.<br />
Hepatol Int 2008;2:263-283.<br />
23. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2.<br />
24. Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors<br />
that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to<br />
peginterferon-alfa. Gastroenterology 2009;137:2002-9.<br />
25. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in<br />
hepatitis B and C. J Hepatol 2008;49:634-51.<br />
26. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, Germanidis G, Yurdaydin C,<br />
Diago M, Gurel S, Lai MY, Brunetto MR, Farci P, Popescu M, McCloud P. Predicting response